Biotech stocks are surging. How investors can play the new drug innovation boom

The iShares Biotechnology ETF (IBB) gained 24% through October 23, on top of a 28% gain in 2025; two dozen of its 233 holdings more than doubled year-to-date, and Moderna rose 587% despite an 18% Thursday drop after a leak of positive cancer-vaccine clinical data. Analysts cite clinical progress, AI-enabled drug discovery and dealmaking—including $134 billion in biopharma M&A in the first half of 2026—as catalysts, while noting biotech development remains risky and failure-prone. Drug developments highlighted include Lilly’s retatrutide, which produced 28%–30% weight loss at the highest doses in trials, and a Moderna-Merck melanoma treatment that reduced cancer recurrence or death by 42% in combination with Keytruda.

Analysis

The key distinction is between a genuine improvement in drug-discovery productivity and a rerating of biotech risk appetite. The former should eventually show up in clinical success rates, time-to-trial, and commercial launches; AI adoption and platform partnerships alone do not establish that. Near term, the sector’s more consequential transmission channel is capital allocation: patent expiries can support selective acquisitions, but deal value accrues to assets with credible data, not to the average small-cap pipeline. A pickup in M&A is therefore not evidence that failures have become less likely.

This creates a barbell opportunity—and a valuation risk. Large, cash-generative companies such as LLY, MRK, and AMGN have more capacity to fund development or acquire assets; early-stage names remain highly exposed to financing conditions and binary trial outcomes. Sequencing and lab-tool vendors ILMN, TXG, and TWST may benefit if more experiments are run, but AI could also make research cheaper without translating promptly into instrument or consumables growth. Watch customer orders and revenue conversion, not partnership announcements.

Over days, momentum and clinical headlines can dominate. Over 1–3 months, trial readouts, guidance, rates, and actual deal terms matter more than broad “innovation-cycle” claims. Over 6–18 months, the test is whether productivity gains generate reproducible approvals and revenues. The contrarian risk is that investors are treating a handful of compelling programs as evidence of a sector-wide reduction in clinical failure risk.

Key Decisions for Investors

• Avoid chasing the broad biotech rally. For a relative-value expression, favor IBB over XBI on a pullback: the former’s larger-company exposure should be more resilient if rates rise or small-cap funding appetite fades. Keep the position modest; a renewed risk-on move or strong small-cap clinical data could make XBI outperform.
• Treat M&A as a catalyst for selected assets, not a blanket small-cap buy signal. Require clinical evidence and inspect deal structure, milestones, and acquisition premiums before underwriting targets; a decline in announced deal value or weaker terms would undermine the sector-wide M&A thesis.
• Keep ILMN, TXG, and TWST on a confirmation list rather than buying AI narratives alone. Look for sustained instrument demand, customer spending, and revenue conversion; weaker orders despite continued AI partnerships would falsify the near-term infrastructure-benefit thesis.
• For MRNA and MRK, wait for complete, independently reviewable trial data and a clearer regulatory path before trading around the personalized-cancer-vaccine opportunity. The thesis weakens if subsequent data fail to confirm the reported benefit or the planned approval timeline slips.